Publications by authors named "Gloria Requena"
Article Synopsis
- Omalizumab is a monoclonal antibody that helps treat moderate-to-severe allergic asthma by inhibiting free immunoglobulin E, showing effectiveness mainly in adolescents and adults, but also in children aged 6-12.
- The article reviews various studies focused on the efficacy and safety of omalizumab in young children, discusses its integration into pediatric asthma management guidelines, and examines its pharmacoeconomic aspects.
- Expert commentary suggests that omalizumab is a safe and effective add-on therapy for children aged 6-12 with poorly controlled asthma, especially when used with other medications like corticosteroids and β2-agonists.
Introduction: Hypersensitivity reactions to beta-lactams (BLs) are often reported in children, with amoxicillin and, to a lesser extent, cephalosporins being the most frequent drugs involved. Although many of these children are considered to be allergic, a careful evaluation only confirms a low percentage.
Objectives: To analyse the clinical data, sensitization profile and diagnostic methods used in a large group of children with a clinical history of hypersensitivity reactions to BLs.
Introduction: Hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequently reported reaction to drugs. They can be induced by pharmacological mechanisms (cyclooxygenase inhibition), with patients classified as cross-intolerant (CI), or by specific immunological mechanisms, IgE or T cell, with patients classified as selective reactors (SR).
Objective: To analyse a large group of children with a history of NSAID hypersensitivity diagnosed by drug provocation test (DPT).